

*Blond*  
13. The method of claim 12 wherein said urinary disease is urinary incontinence or pollakiuria in neurogenic pollakiuria, neurogenic bladder, nocturnal enuresis, unstable bladder, cystospasm or chonic cystitis.--

REMARKS

Newly added claims 12 and 13 are supported by the disclosure and claims as filed. No questions of new matter arise and entry is requested. Claims 12 and 13 replace claims 10 and 11 which the Examiner held to be nonstatutory.

In response to Examiner's restriction requirement, Applicants elect the compound of Example 1, 3-quinuclidinyl 1-phenyl-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate.

The Examiner is invited to contact the undersigned at the telephone number listed below on any question which may arise.

Applicant hereby petitions for any extension of time which may be required to maintain the pendency of this case, and any required fee, except for the Issue Fee, for such extension is to be charged to Deposit Account No. 19-4880.

Respectfully submitted,

*Waddell A. Biggart*  
Waddell A. Biggart  
Registration No. 24,861

SUGHRUE, MION, ZINN,  
MACPEAK & SEAS, PLLC  
2100 Pennsylvania Avenue, N.W.  
Washington, D.C. 20037  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860  
Date: May 26, 1998